Revolution Medicines filed on July 22nd and had FDA approval just over a month later — a five-week review for a pancreatic cancer drug that nearly doubled median survival. Rasonque (daraxonrasib) showed 13.2 months versus 6.7 on chemotherapy in Phase 3 and cleared under the Commissioner's National Priority Voucher program, with RBC modeling roughly $11.5 billion in peak sales for a company that has never commercialized a product. Also in this episode: Spyre Therapeutics shares fell 13% after anti-TL1A antibody SPY072 missed in rheumatoid arthritis, narrowing the mechanism back toward inflammatory bowel disease where Merck, Roche and Sanofi are already in Phase 3. And Biohaven sold global rights to focal epilepsy drug opakalim to SK Biopharmaceuticals for up to $795 million ahead of a year-end pivotal readout.
Alex Mercer and Maya Patel host the Daily Roundup for August 26. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
Podden och tillhörande omslagsbild på den här sidan tillhör
BZ Group. Innehållet i podden är skapat av BZ Group och inte av,
eller tillsammans med, Poddtoppen.
